Paracrine Activin : A Signaling Promotes Melanoma Growth and Metastasis through Immune Evasion

dc.contributor.authorDonovan, Prudence
dc.contributor.authorDubey, Olivier A.
dc.contributor.authorKallioinen, Susanna
dc.contributor.authorRogers, Katherine W.
dc.contributor.authorMuehlethaler, Katja
dc.contributor.authorMüller, Patrick
dc.contributor.authorRimoldi, Donata
dc.contributor.authorConstam, Daniel B.
dc.date.accessioned2022-02-11T09:07:01Z
dc.date.available2022-02-11T09:07:01Z
dc.date.issued2017eng
dc.description.abstractThe secreted growth factor Activin-A of the transforming growth factor β family and its receptors can promote or inhibit several cancer hallmarks including tumor cell proliferation and differentiation, vascularization, lymphangiogenesis and inflammation. However, a role in immune evasion and its relationship with tumor-induced muscle wasting and tumor vascularization, and the relative contributions of autocrine versus paracrine Activin signaling remain to be evaluated. To address this, we compared the effects of truncated soluble Activin receptor IIB as a ligand trap, or constitutively active mutant type IB receptor versus secreted Activin-A or the related ligand Nodal in mouse and human melanoma cell lines and tumor grafts. We found that although cell-autonomous receptor activation arrested tumor cell proliferation, Activin-A secretion stimulated melanoma cell dedifferentiation and tumor vascularization by functional blood vessels, and it increased primary and metastatic tumor burden and muscle wasting. Importantly, in mice with impaired adaptive immunity, the tumor-promoting effect of Activin-A was lost despite sustained vascularization and cachexia, suggesting that Activin-A promotes melanoma progression by inhibiting antitumor immunity. Paracrine Activin-A signaling emerges as a potential target for personalized therapies, both to reduce cachexia and to enhance the efficacy of immunotherapies.eng
dc.description.versionpublishedeng
dc.identifier.doi10.1016/j.jid.2017.07.845eng
dc.identifier.pmid28844941eng
dc.identifier.ppn1789424372
dc.identifier.urihttps://kops.uni-konstanz.de/handle/123456789/56529
dc.language.isoengeng
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectcaALK4, constitutively active mutant Activin receptor-like kinase 4, FST, Follistatin, INHβA, Inhibin βA, TGFβ, transforming growth factor βeng
dc.subject.ddc570eng
dc.titleParacrine Activin : A Signaling Promotes Melanoma Growth and Metastasis through Immune Evasioneng
dc.typeJOURNAL_ARTICLEeng
dspace.entity.typePublication
kops.citation.bibtex
@article{Donovan2017Parac-56529,
  year={2017},
  doi={10.1016/j.jid.2017.07.845},
  title={Paracrine Activin : A Signaling Promotes Melanoma Growth and Metastasis through Immune Evasion},
  number={12},
  volume={137},
  issn={0022-202X},
  journal={Journal of Investigative Dermatology},
  pages={2578--2587},
  author={Donovan, Prudence and Dubey, Olivier A. and Kallioinen, Susanna and Rogers, Katherine W. and Muehlethaler, Katja and Müller, Patrick and Rimoldi, Donata and Constam, Daniel B.}
}
kops.citation.iso690DONOVAN, Prudence, Olivier A. DUBEY, Susanna KALLIOINEN, Katherine W. ROGERS, Katja MUEHLETHALER, Patrick MÜLLER, Donata RIMOLDI, Daniel B. CONSTAM, 2017. Paracrine Activin : A Signaling Promotes Melanoma Growth and Metastasis through Immune Evasion. In: Journal of Investigative Dermatology. Elsevier. 2017, 137(12), pp. 2578-2587. ISSN 0022-202X. eISSN 1523-1747. Available under: doi: 10.1016/j.jid.2017.07.845deu
kops.citation.iso690DONOVAN, Prudence, Olivier A. DUBEY, Susanna KALLIOINEN, Katherine W. ROGERS, Katja MUEHLETHALER, Patrick MÜLLER, Donata RIMOLDI, Daniel B. CONSTAM, 2017. Paracrine Activin : A Signaling Promotes Melanoma Growth and Metastasis through Immune Evasion. In: Journal of Investigative Dermatology. Elsevier. 2017, 137(12), pp. 2578-2587. ISSN 0022-202X. eISSN 1523-1747. Available under: doi: 10.1016/j.jid.2017.07.845eng
kops.citation.rdf
<rdf:RDF
    xmlns:dcterms="http://purl.org/dc/terms/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
    xmlns:bibo="http://purl.org/ontology/bibo/"
    xmlns:dspace="http://digital-repositories.org/ontologies/dspace/0.1.0#"
    xmlns:foaf="http://xmlns.com/foaf/0.1/"
    xmlns:void="http://rdfs.org/ns/void#"
    xmlns:xsd="http://www.w3.org/2001/XMLSchema#" > 
  <rdf:Description rdf:about="https://kops.uni-konstanz.de/server/rdf/resource/123456789/56529">
    <dc:creator>Donovan, Prudence</dc:creator>
    <dc:contributor>Donovan, Prudence</dc:contributor>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2022-02-11T09:07:01Z</dc:date>
    <dc:contributor>Dubey, Olivier A.</dc:contributor>
    <dc:creator>Constam, Daniel B.</dc:creator>
    <dc:rights>Attribution 4.0 International</dc:rights>
    <dcterms:hasPart rdf:resource="https://kops.uni-konstanz.de/bitstream/123456789/56529/1/Donovan_2-ip4ge5btcxs33.pdf"/>
    <dc:contributor>Müller, Patrick</dc:contributor>
    <dc:contributor>Constam, Daniel B.</dc:contributor>
    <dcterms:isPartOf rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/28"/>
    <dc:contributor>Rogers, Katherine W.</dc:contributor>
    <dcterms:issued>2017</dcterms:issued>
    <dc:language>eng</dc:language>
    <dc:creator>Dubey, Olivier A.</dc:creator>
    <dcterms:title>Paracrine Activin : A Signaling Promotes Melanoma Growth and Metastasis through Immune Evasion</dcterms:title>
    <dspace:isPartOfCollection rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/28"/>
    <dc:creator>Kallioinen, Susanna</dc:creator>
    <void:sparqlEndpoint rdf:resource="http://localhost/fuseki/dspace/sparql"/>
    <dspace:hasBitstream rdf:resource="https://kops.uni-konstanz.de/bitstream/123456789/56529/1/Donovan_2-ip4ge5btcxs33.pdf"/>
    <dc:creator>Muehlethaler, Katja</dc:creator>
    <dcterms:rights rdf:resource="http://creativecommons.org/licenses/by/4.0/"/>
    <bibo:uri rdf:resource="https://kops.uni-konstanz.de/handle/123456789/56529"/>
    <dc:contributor>Kallioinen, Susanna</dc:contributor>
    <dc:contributor>Rimoldi, Donata</dc:contributor>
    <foaf:homepage rdf:resource="http://localhost:8080/"/>
    <dc:contributor>Muehlethaler, Katja</dc:contributor>
    <dc:creator>Rogers, Katherine W.</dc:creator>
    <dc:creator>Müller, Patrick</dc:creator>
    <dcterms:abstract xml:lang="eng">The secreted growth factor Activin-A of the transforming growth factor β family and its receptors can promote or inhibit several cancer hallmarks including tumor cell proliferation and differentiation, vascularization, lymphangiogenesis and inflammation. However, a role in immune evasion and its relationship with tumor-induced muscle wasting and tumor vascularization, and the relative contributions of autocrine versus paracrine Activin signaling remain to be evaluated. To address this, we compared the effects of truncated soluble Activin receptor IIB as a ligand trap, or constitutively active mutant type IB receptor versus secreted Activin-A or the related ligand Nodal in mouse and human melanoma cell lines and tumor grafts. We found that although cell-autonomous receptor activation arrested tumor cell proliferation, Activin-A secretion stimulated melanoma cell dedifferentiation and tumor vascularization by functional blood vessels, and it increased primary and metastatic tumor burden and muscle wasting. Importantly, in mice with impaired adaptive immunity, the tumor-promoting effect of Activin-A was lost despite sustained vascularization and cachexia, suggesting that Activin-A promotes melanoma progression by inhibiting antitumor immunity. Paracrine Activin-A signaling emerges as a potential target for personalized therapies, both to reduce cachexia and to enhance the efficacy of immunotherapies.</dcterms:abstract>
    <dcterms:available rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2022-02-11T09:07:01Z</dcterms:available>
    <dc:creator>Rimoldi, Donata</dc:creator>
  </rdf:Description>
</rdf:RDF>
kops.description.openAccessopenaccesshybrideng
kops.flag.isPeerReviewedtrueeng
kops.flag.knbibliographyfalse
kops.identifier.nbnurn:nbn:de:bsz:352-2-ip4ge5btcxs33
kops.sourcefieldJournal of Investigative Dermatology. Elsevier. 2017, <b>137</b>(12), pp. 2578-2587. ISSN 0022-202X. eISSN 1523-1747. Available under: doi: 10.1016/j.jid.2017.07.845deu
kops.sourcefield.plainJournal of Investigative Dermatology. Elsevier. 2017, 137(12), pp. 2578-2587. ISSN 0022-202X. eISSN 1523-1747. Available under: doi: 10.1016/j.jid.2017.07.845deu
kops.sourcefield.plainJournal of Investigative Dermatology. Elsevier. 2017, 137(12), pp. 2578-2587. ISSN 0022-202X. eISSN 1523-1747. Available under: doi: 10.1016/j.jid.2017.07.845eng
relation.isAuthorOfPublication73343573-2e50-4195-a3c4-c3df0ba387d5
relation.isAuthorOfPublication.latestForDiscovery73343573-2e50-4195-a3c4-c3df0ba387d5
source.bibliographicInfo.fromPage2578eng
source.bibliographicInfo.issue12eng
source.bibliographicInfo.toPage2587eng
source.bibliographicInfo.volume137eng
source.identifier.eissn1523-1747eng
source.identifier.issn0022-202Xeng
source.periodicalTitleJournal of Investigative Dermatologyeng
source.publisherElseviereng

Dateien

Originalbündel

Gerade angezeigt 1 - 1 von 1
Vorschaubild nicht verfügbar
Name:
Donovan_2-ip4ge5btcxs33.pdf
Größe:
2.36 MB
Format:
Adobe Portable Document Format
Beschreibung:
Donovan_2-ip4ge5btcxs33.pdf
Donovan_2-ip4ge5btcxs33.pdfGröße: 2.36 MBDownloads: 173

Lizenzbündel

Gerade angezeigt 1 - 1 von 1
Vorschaubild nicht verfügbar
Name:
license.txt
Größe:
3.96 KB
Format:
Item-specific license agreed upon to submission
Beschreibung:
license.txt
license.txtGröße: 3.96 KBDownloads: 0